



20-21th January 2023

Conversations & Trending Topics in GU Cancers

2nd Edition with Uromigos collaboration



With the Scientific Endorsement of:



Fundación para la Excelencia y la Calidad de la Oncología



Headquarters: [Las Palmas de Gran Canaria - AC Hotel Gran Canaria](#)



With an innovating design, and science-based discussion and conversations, this meeting raised in 2021 as a result of a post-pandemic scenario in which technology allowed a quick and easy access to a rapidly evolving knowledge in urologic malignancies, but, at the same time, propitiated lesser interaction and discussion around the open questions in genitourinary cancers.

The 1st Trending Topics in GU Oncology Meeting was held at Gran Canaria in November 2021 in collaboration with Doctor Brian Rini and Professor Thomas Powles, presenters of the Uro-migos TM podcast, and allowed to interchange opinions between them and well-recognized experts in the field in an interactive fashion.

This year, we want to continue supporting this format and raise key open questions in renal and urothelial cancers, but also to expand these debates to prostate cancer.

Scientific Coordinators

Dr. Alfonso Gómez de Liaño. CHU Insular-Materno Infantil, Las Palmas

Dr. Guillermo de Velasco. Hospital 12 de Octubre, Madrid

Guest Speakers

Professor Thomas Powles - Barts Cancer Institute, London.

Dr. Brian Rini - Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

Professor Christopher Sweeney - University of Adelaide's South Australian immunoGENomics Cancer Institute (virtual)

Dr. Javier Puente - Hospital Clínico Universitario San Carlos, Madrid

Dr. Andre Mansinho - Hospital de Santa Maria, Lisboa

Dra. María José Juan Fita - Instituto Valenciano de Oncología, Valencia.

Dr. Elena Castro - Hospital 12 de Octubre, Madrid

Dr. David Lorente - Hospital Provincial de Castellón

Dra. Begoña Mellado - Hospital Clinic, Barcelona

Dr. Daniel Castellano - Hospital 12 de Octubre, Madrid

Dra. Elena Sevillano Fernández - Hospital HM La Rosaleda, Madrid.

Dr. Ignacio Durán Martínez - Hospital Universitario Marqués de Valdecilla, Santander.

Dr. Bernadett Szabados - University College London

Dr. Urbano Anido Herranz - Hospital Universitario de Santiago de Compostela

TECHNICAL SECRETARY

Viajes Medysol

C/ El Pilar 29 38002

Santa Cruz de Tenerife

fed@viajesmedysol.com

+34 922 271 800

SEDE: AC Hotel Gran Canaria - Marriott



C. Eduardo Benot, 3-5, 35007
Las Palmas de Gran Canaria
+34 928 26 61 00



SEOM
Sociedad Española
de Oncología Médica

With the Scientific Endorsement of:
 eco | Fundación para la
Excelencia y la
Calidad de la
Oncología



- Opening 16.25 - Bonifacio Nicolás Díaz Chico - President of the Canarian Foundation of the Canarian Cancer Research Institute
- 16.30-18.00 Trending Topics in Renal Cancer
- 18.00-18.30 Coffee Break
- 18.30-19.15 Challenge the Experts
- 20.30 Dinner (Pick up and drop off at the restaurant)

Trending topics in renal cancer

Discussants: Guillermo de Velasco, Alfonso Gómez de Liaño

Brian Rini, Thomas Powles, Javier Puente, Maria José Juan Fita, Andre Mansinho.

- The old ghost of adjuvant treatment in RCC: is immunotherapy ready?
- Management of Favourable risk metastatic RCC: The more, the better?
- Triplets in advanced RCC: all for one, one for all?
- Quality of life & PROs in mRCC, are we measuring them properly?
- The second-line setting after IO: is there any preference currently? What does the mid-term scenario look-like?
- HIF alpha inhibition, game changer or a small step towards the diamond age?
- Are cytokines dead in RCC?
- Novel immune strategies in advanced RCC, what can we expect?

Saturday 21st January 2023

- 10.00-11.30 Trending Topics in Prostate Cancer
- 11.30-12.00 Coffee Break
- 12.30-14.00 Trending Topics in Bladder Cancer
- 14.00-15.00 Lunch

Trending topics in Prostate Cancer

Discussants: Guillermo de Velasco, Alfonso Gómez de Liaño

Christopher Sweeney (virtual), Elena Castro, David Lorente, Begoña Mellado, Daniel Castellano

- Intensified “TRI-tment” or avoiding chemotherapy in mHSPC, that is the question
- Novel hormonal agents: CYP17 inhibitors VS AR inhibitors, are they equal?
- PARP inhibitors, which is the right biomarker?
- PARP inhibitors without biomarker selection – what happened to synthetic lethality?
- OligoM1 and Oligorecurrent disease: Is the evidence enough to support a metastasis-directed therapy?
- AKT inhibition, is it a realistic target?
- Incorporating PSMA PET into clinical practice.
- PSMA targeted therapies - The Force Awakens
- Are CAR-T Cells the next big leap in Prostate Cancer?



Trending topics in Bladder Cancer

Discussants: Guillermo de Velasco, Alfonso Gómez de Liaño

Thomas Powles, Elena Sevillano, Urbano Anido, Ignacio Durán, Bernadett Szabados

- DFS as an endpoint in adjuvant treatment for bladder cancer
- Bet your money in for muscle invasive disease: neoadjuvant IO-based combos VS IO bladder sparing approaches
- A glimpse into the future: IO-EV versus chemo + IO maintenance
- Platinum eligibility in UC: are we complicating this too much?
- Is Immune therapy as a single agent doomed to extinction?
- Maintenance therapy in mUC: from Avelumab to an opportunity for novel strategies?
- Antibody-drug conjugates, the next big hit?
- FGFR inhibitors: can we successfully develop targeted therapy in urothelial cancer?

